Xencor (XNCR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is XNCR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose…

Xencor (XNCR) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.08 per share a year ago.…

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial res…

Xencor maintains a "Strong Buy" rating following positive phase 1 dose-expansion results for XmAb819 in advanced ccRCC, with pivotal phase 3 plans. XmAb819 achieved a 45.5% cORR at 400 mcg/kg, supporting advancement towa…

Xencor NASDAQ: XNCR reported updated Phase 1 dose-expansion results for its ENPP3-targeting CD3 T-cell engager, XmAb819, in previously treated advanced clear cell renal cell carcinoma at the ESMO 2026 conference. The com…

Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript…

At the ESMO Congress 2026, Xencor Inc. (NASDAQ:XNCR) shared updated results from the Phase 1 study of XmAb819 for advanced clear cell renal cell carcinoma (ccRCC).…

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated resu…

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monda…

Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) were up 4.6% during mid-day trading on Monday. The company traded as high as $24.66 and last traded at $24.8920. 290,326 shares were traded during trading, a declin…

Bank of America Corp DE bought a new stake in shares of Xencor, Inc. (NASDAQ: XNCR) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 360,396 shares of the biopharmaceutica…

Anika Therapeutics (NASDAQ: ANIK - Get Free Report) and Xencor (NASDAQ: XNCR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the st…

Bank of New York Mellon Corp acquired a new position in shares of Xencor, Inc. (NASDAQ: XNCR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commis…

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company…

Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) hit a new 52-week high during trading on Tuesday. The stock traded as high as $23.47 and last traded at $23.12, with a volume of 962153 shares trading hands. The st…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

